Skip to main content
. 2025 Jul 21;45(5):441–453. doi: 10.1097/JCP.0000000000002047

TABLE 1.

Summary of Demographics (All-Treated Analysis Set)

RE104 5 mg (N=6) RE104 11 mg (N=6) RE104 20 mg (N=6) RE104 30 mg (N=9) RE104 35 mg (N=6) RE104 40 mg (N=3) Pooled RE104 (N=36) Pooled Placebo (N=12) All Participants (N=48)
Age (y)
 n 6 6 6 9 6 3 36 12 48
 Mean 37.2 29.0 46.2 34.7 38.2 26.7 36.0 40.1 37.0
 SD 8.47 10.53 10.07 8.96 13.26 1.15 10.92 13.01 11.47
Sex
 Female
  n (%) 0 2 (33.3) 1 (16.7) 3 (33.3) 1 (16.7) 2 (66.7) 9 (25.0) 4 (33.3) 13 (27.1)
 Male
  n (%) 6 (100) 4 (66.7) 5 (83.3) 6 (66.7) 5 (83.3) 1 (33.3) 27 (75.0) 8 (66.7) 35 (72.9)
Ethnicity
 Hispanic or Latino
  n (%) 0 0 0 1 (11.1) 2 (33.3) 0 3 (8.3) 0 3 (6.3)
 Not Hispanic or Latino
  n (%) 6 (100) 6 (100) 6 (100) 8 (88.9) 4 (66.7) 3 (100) 33 (91.7) 12 (100) 45 (93.8)
Race
 Asian
  n (%) 0 0 0 0 0 1 (33.3) 1 (2.8) 0 1 (2.1)
 Black or African American
  n (%) 0 1 (16.7) 0 0 0 0 1 (2.8) 0 1 (2.1)
 White
  n (%) 6 (100) 5 (83.3) 6 (100) 9 (100) 5 (83.3) 2 (66.7) 33 (91.7) 12 (100) 45 (93.8)
 Native Hawaiian or Other Pacific Islander
  n (%) 0 0 0 0 0 0 0 0 0
 Australian Aboriginal or Torres Strait Islander
  n (%) 0 0 0 0 0 0 0 0 0
 American Indian or Alaska Native
  n (%) 0 0 0 0 0 0 0 0 0
 Other
  n (%) 0 0 0 0 1 (16.7) 0 1 (2.8) 0 1 (2.1)